Advertisement

Search Results

Advertisement



Your search for ASCO Post matches 17161 pages

Showing 6301 - 6350


MSK and City College of New York Researchers Awarded $15 Million Grant From NCI

Francesca Gany, MD, MS, Chief of the Immigrant Health and Cancer Disparities Service, and Tim Ahles, PhD, Director of the Neurocognitive Research Laboratory, both of Memorial Sloan Kettering Cancer Center (MSK), along with Gilda Barabino, PhD, and Karen Hubbard, PhD, of the City College of New York ...

breast cancer

Inspired by Her Physician Father, Reshma Jagsi, MD, DPhil, Tirelessly Advocates for Women’s Health and Careers in Medicine

Physician-scientist, Reshma Jagsi, MD, DPhil, was encouraged by her parents to become a politically active, socially conscious citizen of the world. “As a young woman, my mother traveled from Africa on a scholarship to the United States, where she attended the University of Wisconsin. It was in the ...

ASCO Board Concludes Annual Meeting Cannot Occur in Person

On March 24, 2020, ASCO issued the following statement: ASCO’s primary concern is the health and safety of the global oncology community and the patients we serve. As public health safety measures related to COVID-19 extend, the ASCO Board has concluded that the Annual Meeting, scheduled for May 29 ...

Abstracts From the NCCN 2020 Annual Conference Now Available

Abstracts from posters that would have been presented at the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference are now available online. Although NCCN officials were compelled to postpone the conference in response to the coronavirus disease 2019 (COVID-19) pandemic, in order to ...

covid-19

Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter

Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.

prostate cancer
immunotherapy

T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer

Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...

leukemia

New Prognostic Score for Asymptomatic Patients With Early-Stage CLL

A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...

colorectal cancer
immunotherapy

FDA Approves Encorafenib/Cetuximab for BRAF V600E–Mutated Metastatic Colorectal Cancer

On April 8, the U.S. Food and Drug Administration (FDA) approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of pretreated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by an FDA-approved test. BEACON CRC Efficacy was...

hematologic malignancies
covid-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

prostate cancer
bladder cancer
kidney cancer
immunotherapy

Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers

Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...

issues in oncology
global cancer care

Pediatric Cancer Investment Needs and Benefits: Findings From a Commission Created by The Lancet Oncology

Improving care for children with cancer worldwide could bring a triple return on investment and prevent millions of deaths, according to a new Commission report published by Atun et al in The Lancet Oncology. Without additional investment in childhood cancer care, new estimates produced for the...

multiple myeloma
covid-19

Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab

A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...

covid-19

$20 Million in Grants Awarded to Identify Therapies for COVID-19

The partners in the COVID-19 Therapeutics Accelerator—a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard—awarded $20 million in initial grants to three institutions. The University of Washington, the University of Oxford, and La Jolla Institute...

immunotherapy
symptom management

Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction

Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...

multiple myeloma
immunotherapy

Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing

Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...

genomics/genetics
solid tumors
hematologic malignancies

Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages

Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated—often before there are any clinical signs or symptoms of the disease. These findings were published by Liu et al in Annals of Oncology. In their ...

covid-19

Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19

In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...

breast cancer

Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer

An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...

AACR Annual Meeting 2020 to Be Held in a Virtual-Only Format

Today, the American Association for Cancer Research (AACR) Board of Directors issued the following announcement: The AACR has been closely monitoring the rapid escalation of the COVID-19 pandemic. The health and safety of all Annual Meeting attendees and the patients and communities they serve are...

myelodysplastic syndromes
symptom management

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

On April 3, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia that fails to respond to an erythropoiesis-stimulating agent and requires two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk...

issues in oncology
covid-19

Harvard Medical Student’s Innovation: Disinfection You Can See

In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...

breast cancer
bladder cancer
lymphoma
immunotherapy

FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations

The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...

issues in oncology

Apixaban for Cancer-Associated Venous Thromboembolism

For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...

covid-19

Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD

During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...

hematologic malignancies
covid-19

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

On April 1, the ASH Research Collaborative's (ASH RC) Data Hub launched the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy, a global registry with clinical data exclusively on people with COVID-19 and a current or past diagnosis of a hematologic malignancy. The registry is intended to ...

issues in oncology
gynecologic cancers
global cancer care

Gynecologic Cancer Screening After a Natural Disaster

Cervical cancer screening rates were significantly affected in the years following the Great East Japan Earthquake of 2011, according to a report published by Miki et al in PLOS ONE. “Conflicts and disasters, and the social isolation that often follows, have a major impact on health care and lead...

issues in oncology
lung cancer

Disparities in Receipt of Chemotherapy Among Patients With pN1 Lung Cancer

In patients with non–small cell lung cancer (NSCLC) where the cancer has spread to one or more lymph nodes close to the lungs—a condition known as pathologic N1 (pN1) disease—current guidelines recommend a two-part protocol: surgical resection, followed by chemotherapy. However, a retrospective...

multiple myeloma
covid-19

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver...

issues in oncology
geriatric oncology

Polypharmacy and Inpatient Hospitalization Rates in Older Patients With Cancer

In a study published by Grace Lu-Yao, PhD, and colleagues in the Journal of Geriatric Oncology, researchers found hospitalization rates can increase by as much as 114% in patients with breast, prostate, and lung cancers when those patients have taken 15 or more medications prior to chemotherapy...

solid tumors
immunotherapy

Does Pembrolizumab Show Activity in Some Rare Cancers?

A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers. “Our findings that pembrolizumab has a favorable toxicity...

immunotherapy
lung cancer

FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC

On March 27, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). CASPIAN Trial Efficacy of this combination in patients...

Cancer Care Amid the COVID-19 Pandemic

To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy...

hepatobiliary cancer
global cancer care

Trends in Global Rates of Liver Cancer From 1990 to 2017

New research published by Liu et al in the journal Cancer has revealed rising rates of liver cancer around the world, despite advances aimed at preventing the disease; however, some steps towards alleviation have been made due to control of hepatitis. Methods To obtain trends and estimates of liver ...

covid-19

American College of Surgeons Issues COVID-19 Guidelines for Triage of Patients Undergoing Cancer Surgery

This week, the American College of Surgeons issued guidelines on triage of patients undergoing elective cancer surgery during the COVID-19 pandemic. During the current COVID-19 pandemic, hospital leadership and individual providers are facing increasingly difficult decisions about how to conserve...

global cancer care
covid-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

covid-19

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.

gynecologic cancers
immunotherapy

Predicting Which Patients With Ovarian Cancer May Respond to Combination PARP and PD-1 Inhibition

In some patients with advanced ovarian cancer, the combination of programmed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors can produce responses, but up until now, investigators have been unable to predict which patients would not benefit from the treatment and...

covid-19

Association for Clinical Oncology: More Testing, Personal Protective Equipment, Practice Support Needed During COVID-19 Crisis

The Association for Clinical Oncology, ASCO's affiliated 501(c)(6) organization, is urging the White House and leaders in Congress to swiftly work together to meet the needs of patients and health-care professionals in response to the COVID-19 crisis. In a letter to the President, Vice President,...

ASCO, Project ECHO Partner to Pilot Impactful Cancer Tele-Education Program in Nepal

Cancer care for patients in rural areas is challenging—for example, in the United States, only 3% of medical oncologists practice in rural areas, and patients must travel long distances to see specialists. Patients may also have trouble managing complications from care or follow-up from treatment....

The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early-Career Researchers

The parker institute for cancer immunotherapy (PICI) recently announced awards for six early-career researchers through the Parker Scholars, Parker Bridge Fellows, and Parker Senior Fellows programs. They are receiving a total of up to $2.75 million in funding to advance their research in profound...

breast cancer
issues in oncology

Don’t Expect Transgender Patients to ‘Out’ Themselves

Although more transgender patients are presenting to breast centers for imaging, many “report significant social stigma when seeking care,” according to a study in the Journal of Breast Imaging.1 Reported verbal abuse and other forms of harassment “can lead to transgender patients concealing their...

breast cancer
issues in oncology

Addressing the Needs of Transgender Patients for Breast Cancer Screening in Comfortable and Inclusive Environments

An analysis of breast imaging center websites and a literature search for research articles on transgender breast health found that “issues related to transgender breast imaging are not well addressed in the radiology literature or in the radiology community, even though more transgender patients...

breast cancer

I Wasn’t Prepared for the Emotional Turmoil of Breast Cancer

Nearly a decade ago, my mother tested positive for the BRCA1 mutation; soon after, my twin sister and I were tested for the inherited defective gene, and I learned I, too, have the BRCA1 mutation. My sister is not a carrier of the mutation. Although there is a long history of both breast and...

The Opioid Crisis as Told From the Streets to the Clinics and Its Unintended Consequences

The history of drug addictions and epidemics in the United States dates back to the Civil War, when morphine was introduced as a pain medication for wounded soldiers. Regular off-label use of morphine quickly spread from war hospitals to the general public. It is estimated that more than 400,000...

A Cello for Michayla

The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...

colorectal cancer

Expert Point of View: John M. Carethers, MD

The analysis of the National Cancer Database is one of a number of studies describing  sociodemographic-related disparities in colorectal cancer outcomes, according to session Co-Chair John M. Carethers, MD, Professor and Chair of the Department of Internal Medicine at the University of Michigan,...

Veterans Health Bill Promotes Comprehensive Prostate Cancer Care Program

The American Urological Association (AUA) ­announced its support for the Veterans Prostate Cancer Treatment and Research Act, introduced on March 5 by Rep. Neal Dunn, MD (R-FL-3), and Rep. Joe Cunningham (D-SC-1). This bill supports the development and implementation of a Veterans Health...

Randall A. Oyer, MD, Named President of the Association of Community Cancer Centers

At the Association of Community Cancer Centers (ACCC) 46th Annual Meeting & Cancer Center Business Summit, held March 4–6 in Washington, DC, Randall A. Oyer, MD, was named ACCC President for 2020–2021. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the ...

International Association for the Study of Lung Cancer Names Research Award After Fred R. Hirsch, MD, PhD

The International Association for the Study of Lung Cancer (IASLC) recently announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC Chief Executive Officer Fred R. Hirsch, MD, PhD. The award, which was previously named after Adi Gazdar, MD, who...

Charles Sawyers, MD, Receives Knudson Award in Cancer Genetics

The National Cancer Institute (NCI) has named Charles Sawyers, MD, as the recipient of the 2020 Alfred G. Knudson Award in Cancer Genetics. Dr. Sawyers is Chair of the Human Oncology and Pathogenesis Program and the Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, as ...

Advertisement

Advertisement




Advertisement